Bivalent HPV vaccine effective in 18-25 year-old women
MedWire News: Study findings show that women aged 18-25 years with no evidence of current human papilloma virus (HPV) infection benefit from the bivalent HPV vaccine to a similar extent as young women aged 15-17 years.
“A woman can be infected with the virus at any point during her life, and prior infection does not reliably protect her from subsequent infections. There has been ongoing debate over the value of vaccination for women who may previously have been infected with HPV,” said lead study investigator Anne Szarewski (Wolfson Institute of Preventive Medicine, London, UK).
For the study, 18,644 women aged 15-25 years were randomly assigned to receive the bivalent (HPV-16/18) vaccine or the hepatitis A vaccine (controls). Cervical samples were collected every 6 months for HPV-DNA typing and every 12 months for gynecologic/cytopathologic examinations.
Vaccine efficacy in baseline HPV DNA-negative women regardless of serostatus was 89.5 percent and 96.2 percent, calculated using the HPV Type Assignment Algorithm (TAA), an analysis that assigns probable HPV causality in lesions containing multiple HPV types.
Furthermore, vaccine efficacy against HPV-16/18 cervical intraepithelial neoplasia 2+ was 39.4 and 41.6 percent using the HPV TAA, regardless of baseline HPV DNA and serostatus.
“These data support vaccinating 18-25 year-old women, showing such a strategy could help deliver public health benefit by offering them effective protection against cervical cancer,” concluded Szarewski.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
By Ingrid Grasmo